Table 1 Baseline characteristics of included trials
Study | Disease | No. of patients | Type of devices | DAPT(mts) | MACE | Follow-up (mts) | Pre- dilatation (n/lesions) | ||
|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | DEB(+BMS) | DES | Â | Â | Â | DEB | DES |
Adriaenssens 2014 [30] SEDUCE | BMS-ISR | 50 | PEB(SeQuent Please) | EES(XIENCE V/Prime) | NA | NA | 9 (angio), 12 (clinical) | 25/25 | 25/25 |
Alfonso 2015 [31] RIBS IV | DES-ISR | 309 | PEB(SeQuent Please) | EES(XIENCE Prime) | 3 after DEB, 12 after DES | NA | 6–9 angio), 12–36 (clinical) | 154/154 | 155/155 |
Alfonso 2014 [32] RIBS V | BMS-ISR | 189 | PEB(SeQuent Please) | EES(XIENCE Prime) | 3 after DEB, 12 after DES | NA | 6–9 (angio), 12 (clinical) | 95/95 | 94/94 |
Ali 2011 [39] PEPCAD IV | coronary stenoses in patients with DM | 84 | DEB(SeQuent Please) + cobalt-chromium stent(Coroflex Blue) | DES (Taxus Liberté) | 3 after DEB, 6 after DES | NA | 9 | 14/45 | 38/39 |
Belkacemi 2012 [23] DEB-AMI | AMI | 99 | DIOR 2 DEB + cobalt-chromium stent | DES (Taxus Liberté) | 12 | MI, TVR, death | 6 | 30/50 | 49/49 |
Byrne 2013 [33] ISAR-DESIRE 3 | DES-ISR | 268 | DEB(SeQuent Please) | DES (Taxus Liberté) | 6 | Death, MI, TLR | 6–8 (angio), 12–36 (clinical) | 139/172 | 145/168 |
Chae 2017 [24] | De novo lesions | 180 | DEB(Sequent® Please) + BMS(Coroflex® Blue) | ZES(Resolute Integrity) | 9 | TLR, MI, cardiac death | 12 | 74/74 | 72/72 |
Clever 2014 [25] | De novo lesions | 52 | DEB(Braun) + BMS(Coroflex Blue) | SES(Cypher) | 9 | TLR, MI, ST, death | 9 | 16/27 | 16/25 |
Cortese 2010 [37] PICCOLETO | small coronary vessels | 60 | DIOR 1 DEB | DES (Taxus Liberté) | 1 after DEB, 3 after BMS, 12 after DES | Death, STEMI, TLR | 6 (angio), 9(clinical) | 7/28 | 25/29 |
Herdeg 2009 [26] | De novo stenoses | 136 | BMS (Multi-Link Zeta, Guidant)followed by catheter-based local delivery of fluid paclitaxel | DES (Taxus Liberté) | 6 | TLR, MI, subacute closure, or death | 6 | NA | NA |
Latib 2012 [38] BELLO | Small Coronary Vessels | 182 | IN.PACT Falcon DEB | DES (Taxus Liberté) | 1 after DEB, 12 after DES | Death, MI,TVR | 6 (angio), 6–36 (clinical) | 91/94 | 81/98 |
Liistro 2013 [27] | de novo coronary stenosis | 125 | Elutax PEB + cobalt-chromium | EES(XIENCE Prime) | 3 after DEB, 12 after DES | MI, death, TLR | 9 | NA | NA |
Minguez 2014 [41] BABILON | de novo bifurcated coronary lesions | 108 | DEB(SeQuent Please) + cobalt-Chromium stent(Coroflex Blue) | EES(XIENCE Prime) | 3 after DEB, 12 after DES | Death, MI, TLR | 9(angio), 24 (clinical) | 43/43 | 43/43 |
Pleva 2016 [34] | BMS-ISR | 136 | PEB(SeQuent Please) | EES(Promus Element) | 3 after DEB, 6–12 after DES | MI, TVR, Cardiac death | 12 | 69/69 | 68/68 |
Poerner 2014 [28] | coronary artery disease | 90 | DEB(SeQuent Please) + cobalt-chromium stent(Coroflex Blue) | EES(XIENCE Prime) | NA | NA | 6 | NA | NA |
Stella 2012 [40] | coronary bifurcation lesions | 80 | Dior I DEB + Liberte BMS | DES (Taxus Liberté) | 3 after DEB, 12 after DES | MI, TVR, Death | 12 | 33/33 | 37/37 |
Unverdorben 2009 [35] PEPCAD II | ISR | 131 | PEB(SeQuent Please) | DES (Taxus Liberté) | 3 after DEB, 6 after DES | MI, TLR, Cardiac Death, Stent thrombosis | 6 (angio), 12–36 (clinical) | 66/66 | 65/65 |
Xu 2014 [36] PEPCAD China ISR | DES-ISR | 215 | PEB(SeQuent Please) | DES (Taxus Liberté) | 12 | MI, TLR, Cardiac death | 9 (angio), 12 (clinical) | 112/113 | 107/108 |
Zurakowski 2015 [29] | de novo coronary lesions | 202 | DEB(Sequent Please) + BMS | DES(Coroflex Please) | 12 | MI, TVR, Cardiac death | 9 | NA | NA |